ArticleJournal of health economics and outcomes research2026
Cost-Effectiveness Analysis of Trastuzumab-Emtansine as Adjuvant Therapy for HER2-Positive Early Breast Cancer with Residual Invasive Disease in Colombia.
Article in Journal of health economics and outcomes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with HER2-positive (HER2+) breast cancer (BC) who have residual invasive disease after neoadjuvant therapy remain at a significantly increased risk of recurrence. Updated results from the KATHERINE trial demonstrated the clinical benefit of trastuzumab-emtansine (T-DM1), showing a significant improvement in event-free survival. However, in budget-constrained settings, assessing the cost-effectiveness of TDM-1 is essential to guide sustainable adoption. Objective: To evaluate the cost-effectiveness analysis of adjuvant T-DM1 compared with trastuzumab in HER2+ early BC patients and residual disease, following neoadjuvant treatment, from the Colombian Health System perspective. Methods: We conducted a Markov model with a lifetime horizon to evaluate the cost-effectiveness of T-DM1 using the updated results of the KATHERINE trial (8.4-year follow-up). The model comprises 6 health states: patients with residual invasive disease on adjuvant treatment, non-metastatic recurrence, remission after non-metastatic recurrence, metastatic disease (first-line [1LmBC] and subsequent lines [2LmBC]), and death. Direct medical costs were included. The primary outcome was quality-adjusted life-years, with both costs and effects discounted annually at a 5% rate. Model assumptions were based on current guidelines and validated by local experts. Sensitivity and scenario analysis were performed to confirm the reliability of the results. Prices are shown in 2024 US dollars (4071.35 Colombian pesos = US $1). Results: Under a willingness-to-pay threshold of 86% of the 2024 gross domestic product per capita (US Conclusion: T-DM1 is a cost-effective and dominant strategy for the adjuvant treatment of residual invasive HER2+ early BC in Colombia, driven by cost savings from reduced high-cost recurrences. These findings support the adoption of T-DM1 to improve outcomes while ensuring efficient use of healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.